Drug Trial Radar · NCT06854653
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
115
Planned (sponsor's estimate)
Start
Mar 28, 2025
Primary completion
Jan 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Prescient Therapeutics, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles, then 21 day cycle thereafter. Subjects will be treated or followed up, if subjects discontinue treatment, for up to 18 months.
Conditions
- CTCL
Interventions
PTX-100Drug
Peptidomimetic inhibitor of GGTase 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the efficacy of PTX-100 as determined by ORR.Time frame: 18 months from day of first treatment until disease progression, unacceptable toxicity, participant or Investigator decision.
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Cente
Duarte, California · Recruiting
University of California Irvine
Irvine, California · Completed
Yale Cancer Center
New Haven, Connecticut · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Rochester Skin Lymphoma Medical Group. PLLC
Rochester, New York · Recruiting
Virginia Commonwealth University Massey Comprehensive Cancer Cente
Richmond, Virginia · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Epworth Healthcare
Melbourne, Victoria, Australia · Recruiting
Linear Clinical Research
Nedlands, Western Australia, Australia · Recruiting
CHU de Bordeaux - Hopital Saint André
Bordeaux, Bordeaux, France · Not yet recruiting
Hopital Saint Louis
Paris, Île-de-France Region, France · Not yet recruiting
Hopital Lyon Sud
Lyon, Pierre-Benite, France · Not yet recruiting
IRCCS Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi
Bologna, Bologna, Italy · Recruiting
Universita degli Studi Di Brescia-Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Brescia, Brescia, Italy · Recruiting
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario San Raffaele)
Milan, Milano, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.